Cassava Sciences Plummets 23% as the SEC Probes Experimental Alzheimer Drug Data
(WSJ) Shares of Cassava Sciences Inc. fell more than 23% on news that the SEC was examining whether the company manipulated data on their Alzheimer drug. The investigation by the…